



**June 15, 2023**

**Jitsubo announces signing of Exclusive Manufacturing License Agreement in the field of Diabetes, Obesity and the Related Therapeutic Areas with Novo Nordisk**

Jitsubo CO., LTD. a Japan based contract research company (Tsurumi, Kanagawa Pref. , CEO Hideya Mizufune, hereinafter "Jitsubo") announced today, the signing of an exclusive manufacturing license agreement (hereinafter "Agreement") with Novo Nordisk A/S (2880 Bagsvaerd, Denmark, hereinafter "Novo Nordisk") for Novo Nordisk to use and have manufacturing rights to Jitsubo's proprietary peptide manufacturing technology, Molecular Hiving™, for synthesis of peptides in the field of obesity, diabetes, NASH, chronic kidney diseases, atherosclerotic cardiovascular diseases and heart failure.

Novo Nordisk, a leading global healthcare company, and Jitsubo have been collaborating for applying Molecular Hiving™ to synthesis of peptides during the last few years and through this Agreement, the relationship has been further strengthened enabling Jitsubo's Molecular Hiving™ to take steps to advance into commercial applications.

Under the terms of this Agreement, Jitsubo exclusively licenses the Molecular Hiving™ technology to Novo Nordisk in the agreed field of use, allowing Novo Nordisk to proceed into clinical development and commercialization of the peptides.

Jitsubo will receive from Novo Nordisk a development fee, annual exclusivity fee and milestone fee which will depend on the progress of clinical development and

commercialization.

Aside from this Agreement, Jitsubo will continue to explore commercial applications of Molecular Hiving™ for NCE and generics outside the scope of this Agreement.

Molecular Hiving™ has advantages of providing not only low cost and high quality peptides but also green chemistry compliant process comparing to the traditional peptide manufacturing technologies and through these advantages, Jitsubo will contribute to the future pharmaceutical industries and the patients.